EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC early clinical studies group

European Journal of Cancer Part A

Volumn 32, Issue 11, 1996, Pages 2019-2022

  Dirix, L Y ^a   Tonnesen, F ^b   Cassidy, J ^c   Epelbaum, R ^d   Ten Bokkel Huinink, W W ^e   Pavlidis, N ^k   Sorio, R ^f   Gamucci, T ^g   Wolff, I ^h   Te Velde, A ⁱ   Lan, J ⁱ   Verweij, J ^j  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d RAMBAM MEDICAL CENTER   (Israel)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

^f CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^g REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^h KLINIKUM NÜRNBERG   (Germany)

ⁱ New Drug Development Office   (Netherlands)

^j ERASMUS MC CANCER INSTITUTE   (Netherlands)

^k NONE

more..

Author keywords

Breast cancer; Colorectal cancer; EO9; Gastric cancer; Pancreatic cancer; Phase II study; Proteinuria; Renal toxicity

Indexed keywords

5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CLINICAL TRIAL; COLORECTAL CANCER; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; STOMACH CANCER; VOMITING;

EID: 0030271681     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00226-2     Document Type: Article

References (12)

1. 1. Oostveen EA, Speckamp WN. Mitomycin C analogues 1. Indoloquinones as potential bisalkylating agents. Tetrahedron 1987, 43, 255-262.
2. 2. Moody CJ, O'Sullivan N, Stratford IJ, et al. Cyclopropamitosenes: novel bioreductive anticancer agents-mechanisms of action and enzymatic reduction, Anti-Cancer Drugs 1994, 5, 367-372.
3. 3. Maliepaard M, Wolfs A, Groot SE, De Mol NJ, Janssen LHM. Indoloquinone EO9: DNA interstrand cross-linking upon reduction by DT-diaphorase or xanthine oxidase. Br J Cancer 1995, 71, 836-839.
4. 4. Phillips RM, Hulbert PB, Bibby MC, et al. In vitro activity of the novel indoloquinone EO-9 and the influence of pH on cytotoxicity. Br J Cancer 1992, 65, 359-364.
5. 5. Plumb JA, Gerritsen M, Milroy R., Thompson P, Workman P. Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung cancer cell lines. Int J Radiat Oncol Biol Phys 1994, 29, 295-299.
6. 6. Smitskamp-Wilms E, Peters GJ, Pinedo HM, Van Ark-Otte J, Giaccone G. Chemosensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and its gene expression. Biochem Pharmacol 1994, 47, 1325-1332.
7. 7. Hendriks HR, Pizao PE, Berger DP, et al. EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour toxicity in preclinical models. Eur J Cancer 1993, 29A, 897-906.
8. 8. Schellens JHM, Planting ASTh, van Acker BAC, et al. Phase I and pharmacological study of the novel indoloquinone bioreductive alkylating cytotoxic drug EO9. J Natl Cancer Inst 1994, 86, 906-912.
9. 9. Smitskamp-Wilms E, Giaccone G, Pinedo HM, van der Laan BFAM, Peters GJ. DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents? Br J Cancer 1995, 72, 917-921.
10. 10. Plumb JA, Workman P. Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity. Int J Cancer 1994, 56, 134-139.
11. 11. Plumb JA, Gerritsen M, Workman P, Is the hydroquinone or semiquinone the most potent cytotoxic metabolite of indoloquinone EO9? Proc Am Assoc Cancer Res 1994, 35, A2290.
12. 12. Collard J, Matthew AM, Double JA, Bibby MC. EO9: relationship between DT-diaphorase levels and response in vitro and in vivo. Br J Cancer 1995, 71, 1199-1203.